Merck, Roche and BMS have unveiled updated results in Copenhagen as the companies duke it out for the leadership in lung cancer therapies.
The conference of the European Society of Medical Oncology (ESMO) is underway in Copenhagen, and big pharma’s efforts to cure lung cancer are stealing the show. Three titans, Roche (Genentech), Merck and Bristol-Meyers Squibb are going head to head in a competition to corner the market for non-small cell lung cancer (NSCLC) treatments, which would address around 90% of lung cancers. Let’s meet their candidates.
The head of immunotherapy development for Roche’s Genentech, Dan Chen, called Tecentriq‘s recent success “essentially unprecedented”: after it reached its co-primary endpoint in Phase III last month, the PD-L1 therapy has increased the survival rate of NSCLC patients by almost 50%, from 9.6 months to 13.8 in further studies. Patients enrolled in this trial did not necessarily express the PD-L1 biomarker and had previously failed one or two other treatments. This is indeed a major success for Roche,